{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ashraf-Uz-Zaman M"],"funding":["American Cancer Society","National Institute of Mental Health","NCI NIH HHS","National Institutes of Health"],"pagination":["112866"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7744370"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["209"],"pubmed_abstract":["Triple-negative breast cancer (TNBC) is an aggressive type of cancer characterized by higher metastatic and reoccurrence rates, where approximately one-third of TNBC patients suffer from the metastasis in the brain. At the same time, TNBC shows good responses to chemotherapy, a feature that fuels the search for novel compounds with therapeutic potential in this area. Recently, we have identified novel urea-based compounds with cytotoxicity against selected cell lines and with the ability to cross the blood-brain barrier in vivo. We have synthesized and analyzed a library of more than 40 compounds to elucidate the key features responsible for the observed activity. We have also identified FGFR1 as a molecular target that is affected by the presence of these compounds, confirming our data us"],"journal":["European journal of medicinal chemistry"],"pubmed_title":["Design, synthesis and structure-activity relationship study of novel urea compounds as FGFR1 inhibitors to treat metastatic triple-negative breast cancer."],"pmcid":["PMC7744370"],"funding_grant_id":["RSG-15-009-01-CDD","R01CA214019","1R15CA231339-0","CPRIT RP170003","HHSN-271-2013-00017-C","R01 CA226436","R01 CA186662","R15 CA231339","R01 CA214019"],"pubmed_authors":["Shahi S","Farshbaf MJ","Sajib MS","Putnam W","Mikelis CM","Ashraf-Uz-Zaman M","German NA","Zhang R","Kallem RR","Akwii R","Trippier PC","Alvina K","Wang W"],"additional_accession":[]},"is_claimable":false,"name":"Design, synthesis and structure-activity relationship study of novel urea compounds as FGFR1 inhibitors to treat metastatic triple-negative breast cancer.","description":"Triple-negative breast cancer (TNBC) is an aggressive type of cancer characterized by higher metastatic and reoccurrence rates, where approximately one-third of TNBC patients suffer from the metastasis in the brain. At the same time, TNBC shows good responses to chemotherapy, a feature that fuels the search for novel compounds with therapeutic potential in this area. Recently, we have identified novel urea-based compounds with cytotoxicity against selected cell lines and with the ability to cross the blood-brain barrier in vivo. We have synthesized and analyzed a library of more than 40 compounds to elucidate the key features responsible for the observed activity. We have also identified FGFR1 as a molecular target that is affected by the presence of these compounds, confirming our data us","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Jan","modification":"2026-05-02T11:47:31.282Z","creation":"2022-02-11T14:23:12.536Z"},"accession":"S-EPMC7744370","cross_references":{"pubmed":["33039722"],"doi":["10.1016/j.ejmech.2020.112866"]}}